CompanyGraph
Alembic Pharmaceuticals Ltd.
APLLTD · NSE India · India
alembicpharmaceuticals.comFinancials as of FY2026
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.69B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.3: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.46%Above 5Y avg (1.40%)
Annual Rate
INR 12.00Paid annual
Payout Ratio
31.2%Sustainable
Payback Period
68.5 yr
Last Ex-Dividend
Jul 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
161.53BINR1.69B · vs all stocks (USD)
Trailing P/E
23.30xRevenue (TTM)
77.84BINR813.11M · vs all stocks (USD)
Profit Margin
8.91%Beta
0.3010xvs all stocks
52-Week Change
-15.68%vs all stocks
Market Capitalization
161.53BINR1.69B · vs all stocks (USD)
Enterprise Value
172.30BINR1.80B · vs all stocks (USD)
Trailing P/E
23.30xForward P/E
17.06xPEG Ratio
2.27xPrice to Sales (TTM)
2.07xPrice to Book (MRQ)
2.84xEnterprise to Revenue
2.21xEnterprise to EBITDA
15.19xGross Margin
71.16%Profit Margin
8.91%Operating Margin
10.89%Return on Assets (TTM)
7.73%Return on Equity (TTM)
11.90%Revenue (TTM)
77.84BINR813.11M · vs all stocks (USD)
Revenue per Share (TTM)
396.00INRUpdated Aug 21, 2026Quarterly Revenue Growth
25.70%Gross Profit (TTM)
54.92BINR573.73M · vs all stocks (USD)
EBITDA (TTM)
11.96BINR124.96M · vs all stocks (USD)
Net Income (TTM)
6.93BINR72.44M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
12.10%Operating Cash Flow (TTM)
7.83BINR81.76M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
6.75BINR70.49M · vs all stocks (USD)
Trailing Annual Dividend Rate
12.00INRUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.46%vs all stocks
5-Year Average Dividend Yield
1.40%vs all stocks
Payout Ratio
31.18%Minority Interest (Equity)
-58.30MINRFY2026 · Mar 31, 2026Revenue
72.13BINRFY2026 · Mar 31, 2026Cost of Goods Sold
23.60BINRFY2026 · Mar 31, 2026Gross Profit
48.53BINRFY2026 · Mar 31, 2026Operating Income
8.04BINR83.98M · vs all stocks (USD)
Pre-tax Income
6.94BINRFY2026 · Mar 31, 2026Income Tax Expense
231.20MINRFY2026 · Mar 31, 2026Net Income
6.71BINRFY2026 · Mar 31, 2026EBIT
7.88BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
11.74BINRFY2026 · Mar 31, 2026Research & Development
378.30MINRFY2026 · Mar 31, 2026Selling, General & Administrative
14.12BINRFY2026 · Mar 31, 2026Other Operating Expenses
6.81BINRFY2026 · Mar 31, 2026Non-operating Interest Income
8.60MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
936.30MINRFY2026 · Mar 31, 2026EPS (Basic)
34.33INRFY2026 · Mar 31, 2026EPS (Diluted)
34.33INRFY2026 · Mar 31, 2026Basic Shares Outstanding
196.56MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
196.56MSharesFY2026 · Mar 31, 2026Minority Interests (P&L)
39.40MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
5.49BINRFY2026 · Mar 31, 2026Free Cash Flow
1.16BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
1.96BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
6.94BINRFY2026 · Mar 31, 2026Other Non-cash Items
1.11BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
77.30MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-2.64BINRFY2026 · Mar 31, 2026Capital Expenditures
-4.32BINRFY2026 · Mar 31, 2026Net Intangibles (CF)
-602.60MINRFY2026 · Mar 31, 2026Purchase of Investments
-144.40MINRFY2026 · Mar 31, 2026Other Investing Activity
-200.00KINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-4.47BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
1.42BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
230.40MINRFY2026 · Mar 31, 2026Common Dividends Paid
-2.16BINRFY2026 · Mar 31, 2026Other Financing Charges
-2.90MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-512.20MINRFY2026 · Mar 31, 2026Shares Outstanding
196.56MSharesUpdated Aug 21, 2026Float Shares
57.65MSharesUpdated Aug 21, 2026% Held by Insiders
70.67%vs all stocks
% Held by Institutions
17.08%vs all stocks
Total Cash (MRQ)
1.96BINR20.51M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.99INRUpdated Aug 21, 2026Total Debt (MRQ)
14.30BINR149.37M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2522xCurrent Ratio (MRQ)
1.75xBook Value per Share (MRQ)
288.70INRUpdated Aug 21, 2026Total Assets
87.33BINR912.21M · vs all stocks (USD)
Total Current Assets
45.43BINRFY2026 · Mar 31, 2026Total Liabilities
30.94BINRFY2026 · Mar 31, 2026Total Non-current Assets
41.90BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
5.00BINRFY2026 · Mar 31, 2026Total Current Liabilities
25.94BINRFY2026 · Mar 31, 2026Cash
1.96BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
1.96BINRFY2026 · Mar 31, 2026Other Short-term Investments
202.20MINRFY2026 · Mar 31, 2026Accounts Receivable
14.66BINRFY2026 · Mar 31, 2026Inventory
25.11BINRFY2026 · Mar 31, 2026Accounts Payable
8.35BINRFY2026 · Mar 31, 2026Short-term Debt
12.63BINRFY2026 · Mar 31, 2026Other Current Liabilities
-100.00KINRFY2026 · Mar 31, 2026Long-term Debt
1.67BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
1.80BINRFY2026 · Mar 31, 2026Common Stock (Book)
393.10MINRFY2026 · Mar 31, 2026Retained Earnings
48.54BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
56.69BINR592.18M · vs all stocks (USD)
52-Week Low
635.80INRUpdated Aug 21, 202652-Week High
998.00INRUpdated Aug 21, 202652-Week Change
-15.68%vs all stocks
Beta
0.3010xvs all stocks
50-Day MA
808.51INRUpdated Aug 21, 2026200-Day MA
786.17INRUpdated Aug 21, 2026Avg 10-Day Volume
86.29KSharesUpdated Aug 21, 2026Avg 30-Day Volume
106.67KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
35.17INRUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.3: safe zoneNotable
Altman Z-Score: 5.30
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.69B, above the global median of $1.15BNotable
Market cap (USD): 1,687,297,954.698Global Median: 1,146,734,693.424
Revenue is $813.11M, above the global median of $520.53MNotable
Revenue (USD): 813,111,409.312Global Median: 520,528,949.311
Levered free cash flow is $70.49M, above the global median of $16.24MNotable
Levered free cash flow (USD): 70,486,474.2Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai MicroPort Endovascular MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cofoe Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Henan Lingrui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Boji Medical & Technology Co., Ltd.
2 interpretationsMinimal Tax and Interest DragMulti-Year Revenue, Profit, And Income Growth
Beijing Sun-Novo Pharmaceutical Co., Ltd.
2 interpretationsMinimal Tax and Interest DragMulti-Year Revenue, Profit, And Income Growth
Acro Biosystems Co., Ltd.
2 interpretationsMinimal Tax and Interest DragMulti-Year Revenue, Profit, And Income Growth